| Literature DB >> 31440278 |
Zohreh Nourmohammadi1, Asghar Khalifehzadeh-Esfahani2, Mehdi Eftekhari3, Hamid Sanei4.
Abstract
BACKGROUND: Management of atrial fibrillation (AF), besides prevention of stroke, mainly stresses symptom control and improvement of quality of life (QOL). In patients with permanent AF, exercising may improve QOL, rhythm, and symptoms. The purpose of this study was to determine the impact of aerobic physical rehabilitation on the QOL of patients suffering from AF and admitted to a coronary care unit (CCU).Entities:
Keywords: Aerobic Exercise; Atrial Fibrillation; Coronary Care Units; Quality of Life; Rehabilitation
Year: 2019 PMID: 31440278 PMCID: PMC6597798 DOI: 10.22122/arya.v15i1.1705
Source DB: PubMed Journal: ARYA Atheroscler ISSN: 1735-3955
Figure 1CONSORT diagram of the study
The mean of some demographic and clinical characteristics variables in the two groups
| Variable | Experimental group (n = 25) | Control group (n = 25) | P |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| Age (year) | 57.2 ± 7.4 | 59.9 ± 7.5 | 0.200 |
| Weight (kg) | 78.1 ± 13.0 | 75.4 ± 8.3 | 0.380 |
| Height (cm) | 165.9 ± 8.6 | 165.4 ± 7.9 | 0.840 |
| Abdominal circumference (cm) | 96.7 ± 8.3 | 95.7 ± 6.3 | 0.650 |
| BMI (kg/m2) | 28.4 ± 4.6 | 27.6 ± 2.7 | 0.440 |
| Atrial fibrillation duration (year) | 2.2 ± 1.3 | 2.6 ± 2.0 | 0.420 |
| PT | 23.0 ± 5.6 | 24.7 ± 2.7 | 0.180 |
| INR | 1.9 ± 0.5 | 1.9 ± 0.3 | 0.630 |
| EF | 54.0 ± 6.3 | 50.9 ± 7.3 | 0.110 |
BMI: Body mass index; PT: Prothrombin time; INR: International normalized ratio; EF: Ejection fraction; SD: Standard deviation
Frequency of some clinical characteristics and past medical history variables in the two groups
| Variable | Experimental group (n = 25) | Control group (n = 25) | P | ||
|---|---|---|---|---|---|
| n (%) | n (%) | ||||
| Sex (male) | 10 (40) | 13 (52) | 0.400 | ||
| Medical history | |||||
| Hyperlipidemia | 5 (20) | 8 (32) | 0.330 | ||
| Hypertension | 19 (76) | 20 (80) | 0.730 | ||
| Diabetes | 3 (12) | 5 (20) | 0.350 | ||
| Smoking | 2 (8) | 4 (16) | 0.330 | ||
| Overweight | 13 (52) | 12 (48) | 0.780 | ||
| Clinical symptoms | |||||
| Dyspnea | 16 (64) | 18 (72) | 0.540 | ||
| Palpitation | 16 (84) | 20 (80) | 0.210 | ||
| Dizziness | 9 (36) | 11 (44) | 0.560 | ||
| Weakness | 11 (44) | 10 (40) | 0.770 | ||
| No symptoms | 2 (8) | 3 (12) | 0.500 | ||
| Medication at baseline | |||||
| Antiplatelet | 12 (48) | 8 (32) | 0.250 | ||
| Flecainide | 1 (4) | 0 (0) | 0.500 | ||
| Amiodarone | 2 (8) | 3 (12) | 0.500 | ||
| Sotalol | 0(0) | 0 (0) | > 0.990 | ||
| Digoxin | 5 (20) | 7 (28) | 0.510 | ||
| Calcium Blocks | 7 (28) | 3 (12) | 0.160 | ||
| β-Blockers | 9 (36) | 6 (24) | 0.350 | ||
| ACE I-ARB | 14 (56) | 16 (64) | 0.560 | ||
| α-Blocking agents | 7 (28) | 9 (36) | 0.540 | ||
| Statin | 7 (28) | 9 (36) | 0.500 | ||
| Warfarin | 24 (96) | 25 (100) | 0.500 |
Overweight: Body mass index (BMI) > 25 kg/m2
ACE-Is: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers
Fisher’s exact test; Other items: Chi-square test
The mean of total quality of life score and its domains before and after the intervention in the two groups
| Aspects of quality of life | Group | Before the intervention | After the intervention | P | Mean differences | P |
|---|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | ||||
| Physical function | Experimental | 62.5 ± 4.10 | 88.9 ± 1.7 | < 0.001 | 26.4 ± 3.1 | < 0.001 |
| Control | 61.2 ± 4.30 | 59.7 ± 4.3 | 0.450 | -1.5 ± 1.9 | ||
| Limitation due to physical problems | Experimental | 40.4 ± 5.90 | 66.0 ± 6.3 | < 0.001 | 25.6 ± 3.9 | < 0.001 |
| Control | 37.0 ± 6.50 | 35.0 ± 7.1 | 0.630 | -2.0 ± 4.1 | ||
| Limitation due to mental problems | Experimental | 39.5 ± 6.60 | 76.0 ± 7.1 | < 0.001 | 36.5 ± 5.9 | < 0.001 |
| Control | 36.0 ± 7.90 | 36.0 ± 8.1 | > 0.990 | 0 ± 0 | ||
| Vitality | Experimental | 60.4 ± 3.40 | 67.4 ± 3.2 | 0.020 | 7.0 ± 2.8 | 0.040 |
| Control | 57.2 ± 3.70 | 56.4 ± 3.3 | 0.760 | -0.8 ± 2.6 | ||
| Mental health | Experimental | 58.1 ± 4.70 | 62.1 ± 4.2 | 0.340 | 4.0 ± 1.4 | 0.490 |
| Control | 57.9 ± 3.90 | 58.4 ± 3.2 | 0.870 | 0.5 ± 2.9 | ||
| Social health | Experimental | 62.5 ± 4.02 | 80.5 ± 3.5 | < 0.001 | 18.0 ± 3.2 | < 0.001 |
| Control | 60.8 ± 2.90 | 62.5 ± 3.5 | 0.580 | 1.7 ± 3.1 | ||
| Body pain | Experimental | 62.0 ± 4.40 | 78.8 ± 2.8 | 0.001 | 16.8 ± 4.4 | 0.008 |
| Control | 60.5 ± 3.70 | 61.0 ± 3.7 | 0.900 | 0.5 ± 3.9 | ||
| Overall health | Experimental | 43.4 ± 3.80 | 55.9 ± 4.4 | 0.006 | 12.5 ± 4.2 | 0.010 |
| Control | 44.8 ± 2.90 | 44.0 ± 2.4 | 0.780 | -0.8 ± 2.8 | ||
| Total quality of life score | Experimental | 53.2 ± 3.20 | 72.6 ± 2.5 | < 0.001 | 19.4 ± 1.8 | < 0.001 |
| Control | 51.9 ± 2.80 | 52.2 ± 2.7 | 0.800 | 0.3 ± 1.4 |
Paired samples t-test;
Independent samples t-test;
SD: Standard deviation